I am delighted that our proposal was selected from a strong field,” Dr. Tate said. Our team looks forward to welcoming colleagues from around the world.
Alachua, Fla. (PRWEB) June 05, 2014
CTD Holdings, Inc. (OTCQB: CTDH), a distributor and manufacturer of cyclodextrin products including the orphan drug designated Trappsol(R) Cyclo(TM), today announced that President and Director Dr. Jeffrey Tate has been named Chairman of the 18th International Cyclodextrin Symposium to be held in Gainesville, Fla. in 2016. The Symposium Advisory Board reviewed three proposals to host the 2016 meeting and selected Dr. Tate’s presentation based on the extensive preparation that has already been done. “I am delighted that our proposal was selected from a strong field,” Dr. Tate said. “Researchers and businesses in Gainesville played important roles in the early days of cyclodextrin commercialization. Holding the Symposium here recognizes those historical contributions and the bright future of cyclodextrins being created by the CTD Holdings Family of Companies. Our team looks forward to welcoming colleagues from around the world.”
The International Cyclodextrin Symposium is a global gathering of academic and industry researchers to present and discuss the latest developments in cyclodextrin research and applications. Attendees are the opinion leaders in this rising field of interest; they include biologists, chemists, material scientists and engineers. The Symposium is held every two years with the venue selected from proposals solicited by the Advisory Board.
The 18th International Cyclodextrin Symposium will be held at the Hilton University of Florida Conference Center in Gainesville, May 17-21, 2016. For further information about registration, sponsorship or presentation opportunities contact Dr. Tate - service(at)cyclodex(dot)com.
About the Company:
The CTD Holdings, Inc. Family of Companies distributes and manufactures the trademarked Trappsol(R) and Aquaplex(R) cyclodextrins, cyclodextrin derivatives, and cyclodextrin complexes for research, nutrition, cosmetic and medical markets. Sphingo Biotechnology, Inc. is developing Trappsol(R) Cyclo(TM), an orphan drug designated product, for the treatment of Niemann Pick Type C, a fatal genetic disease in young children. NanoSonic Products, Inc. operates the world's only cGMP pulse drying facility for the production of ultra-pure cyclodextrin derivatives and pharmaceutical grade Aquaplex(R) cyclodextrin complexes. CTD, Inc. supplies researchers around the globe from the world’s largest catalog of cyclodextrins. The companies offer a wide variety of cyclodextrin related manufacturing services to worldwide customers, including custom formulation, manufacturing, and commercial scale supply of pharmaceutical grade cyclodextrin complexes. For additional information, visit the Company's websites: http://www.ctd-holdings.com and http://www.cyclodex.com.
Safe Harbor Statement:
This press release contains "forward-looking statements" about the Company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the Company's future performance include the Company's ability to obtain additional capital to expand operations as planned, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing food and pharmaceutical grade products. These and other risk factors are described from time to time in the Company's filings with the Securities and Exchange Commission, including, but not limited to, the Company's reports on Forms 10-K and 10-Q. Unless required by law, the Company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.
Contact:
Sitrick And Company
Wendy Tanaka, (415) 369-8447, wtanaka(at)sitrick(dot)com
Thomas Mulligan, (212) 573-6100, Ext. 395, tmulligan(at)sitrick(dot)com
Source: CTD Holdings, Inc.